Loading data for CNXU — first visit, this takes a few seconds.
Conexeu Sciences Inc.
4.97 -0.30 (-5.69%)
4.99 +0.40%
- Market Cap
- $133.0M
- Volume
- 249K
- Dividend yield
- n/a
Conexeu Sciences Inc. (CNXU) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 6.29
- Market Cap
- 133M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -7.2M
- n/a
- -0.34
- n/a
- -9.38
- P/B (ttm)
- 14.45
- P/S (ttm)
- n/a
- Earnings Date
- n/a
- Ask
- 5.82
- Volume
- 249,398
- Avg. Volume (20D)
- 160,198
- Open
- 5.26
- Previous Close
- 5.27
- Day's Range
- 4.86 - 5.58
- 52-Week Range
- 4.86 - 18.79
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Conexeu Sciences Inc.
View profile →Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Industry Biotechnology
Sector Healthcare
IPO Date May 21, 2026
Employees n/a
Stock Exchange NasdaqCM
Ticker Symbol CNXU
Website https://www.conexeu.com